D Dimer Role in Coagulation Activation and Secondary Fibrinolysis
Bruno Pougault, Global Marketing Hemostasis Product Manager at HORIBA, reposted from Horiba on LinkedIn:
”D dimer is an important biomarker of coagulation activation and secondary fibrinolysis that is routinely used to rule out venous thromboembolism (VTE), and to evaluate the risk of VTE recurrence, as well as the optimal duration of anticoagulant therapy.”
Horiba for Healthcare shared on LinkedIn:
”[Register now!] Free Online Workshop
D-Dimer: Diagnostic Challenges and Clinical Relevance
Thursday, October 16, 11–12 AM CEST
Register here.
This online workshop will focus on D dimer, a byproduct of the blood clotting and breakdown process that serves as a marker of ongoing coagulation and fibrinolysis.
The session will explore its clinical use in ruling out deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as the inherent challenges—such as poor specificity, false positives, and difficulties in interpretation, especially in older patients or those with conditions like COVID-19 or cancer.
Participants will learn how to improve diagnostic accuracy and patient management through the use of clinical pretest probability assessments.
The workshop will also discuss the application of age-adjusted D dimer thresholds and the importance of confirmatory imaging in guiding clinical decisions.
Who should attend?
Healthcare professionals involved in D-dimer testing and thromboembolic disease management, such as pathologists, hemostasis lab scientists, acute care nurses, emergency physicians, hospitalists, hematologists, cardiologists, geriatricians, general practitioners, and trainees in related specialties.”
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 29, 2025, 12:43Advancing Thrombosis Research: MRI-Based Methodology for Studying Thrombus Resolution
-
Sep 29, 2025, 05:58Samwel Mikaye on Understanding, Diagnosing, and Managing Deep Venous Thrombosis (DVT)
-
Sep 28, 2025, 14:08Mary Cushman: Dr Warkentin Is a Giant in Hematology
-
Sep 28, 2025, 13:31Michael Makris Highlights Vaccine Misinformation and Its Risks
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 06:23Yudi Hardianto and Colleagues Give a Review on Stroke Rehabilitation in LMICs
-
Sep 29, 2025, 04:42Wolfgang Miesbach on the Bi8 Study: A Novel FVIII-Mimetic Antibody Gene Therapy for Haemophilia A
-
Sep 29, 2025, 04:16Salvador Payán Pernía on Equity Challenges in Access to Gene Therapy for Hemoglobinopathies
-
Sep 29, 2025, 04:02Nicolas Gendron: A Very Nice Demonstration by The Authors - Coffee is Associated with Reduced Risk of VTE
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heart․ Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe
-
Sep 28, 2025, 10:33Côme Bommier: Burnout Is Common Among Hematology Professionals